Background: Dose adjustment or laboratory monitoring of low-molecular-weight heparin
(LMWH) is commonly recommended for patients with severe renal insufficiency (creatinine …

Objective To develop practical recommendations for the use of low-molecular-weight
heparins (LMWHs) as prophylaxis and treatment of venous thromboembolism and acute …

The clearance of therapeutic monoclonal antibodies (mAbs) typically does not involve
cytochrome P450 (CYP450)-mediated metabolism or interaction with cell membrane …

Aims To determine the effects of age on outcomes in patients with STEMI treated with a
strategy of enoxaparin (ENOX) vs. unfractionated heparin (UFH). Methods and results In the …

We extend the development of the expression of the Fisher information matrix in nonlinear
mixed effects models for designs evaluation. We consider the dependence of the marginal …

Low-molecular-weight heparins (LMWHs) accumulate in patients with impaired renal
function. As this accumulation depends on heparin chain length and subsequent reticulo …

Enoxaparin is frequently prescribed for pregnant women who are at high risk for
thromboembolic complications. We conducted a population pharmacokinetics study with 75 …

Low-molecular weight heparins (LMWHs) have been shown to be as safe and effective as
unfractionated heparin (UFH) for the treatment of acute venous thrombosis and non-life …

New oral antithrombotics: a need for laboratory monitoring. For - ScienceDirect Skip to main
contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving
fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and …